NK Cells: Born to Kill

Natural Killer (NK) cells have been considered a part of the innate immune system due to their lack of antigen specific receptors. Unlike other lymphocytes that develop in the bone marrow from lymphoid progenitor cells, NK cells are large with distinctive granules containing perforin and granzymes. The cytotoxic granules bind and penetrate target cells to […]

OrganaBio Overview – Transforming a World of Research into a World of Cellular Therapies

In this presentation, OrganaBio’s CEO, Justin Irizarry, gives an overview of OrganaBio’s capabilities and how they can be leveraged to support the development and commercialization of cutting-edge cell and gene therapies. This talk was originally given at the 2021 Cell and Gene Meeting on the Mediterranean global conference. The conference brought together over 500 members […]

Who We Are

OrganaBio was founded in 2018 by scientists and business leaders motivated to bring next generation regenerative medicine therapies to market. Since then, we have assembled a team of 16 industry veterans, from scientists and engineers with years of bioprocess and therapeutic development experience to those versed in Quality Assurance, Quality Control, Regulatory Affairs and successful […]